Cygnus Technologies’ new AccuRes™ Host Cell DNA Quantification Kits offer a
state-of-the-art solution to precisely and accurately quantify host cell DNA remaining during biopharmaceutical process development or in final drug substances. This all-in-one kit combines Cygnus’ proprietary extraction procedure with a probe-based master mix to recover, amplify, and quantify femtogram levels of host cell DNA. AccuRes™ Host Cell DNA Quantification Kits are offered in well or tube-based extraction formats, and are compatible with a variety of qPCR instruments, offering flexibility and cost savings without compromising sensitivity.
Learn more: Cygnus Technologies’ AccuRes Kits
Cygnus Technologies, part of Maravai LifeSciences, provides off-the-shelf analytical
solutions and custom services for host cell protein (HCP) and other process-related
impurity detection, as well as BSL-1 compatible viral clearance solutions. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release.
Visit online: Cygnus Technologies
state-of-the-art solution to precisely and accurately quantify host cell DNA remaining during biopharmaceutical process development or in final drug substances. This all-in-one kit combines Cygnus’ proprietary extraction procedure with a probe-based master mix to recover, amplify, and quantify femtogram levels of host cell DNA. AccuRes™ Host Cell DNA Quantification Kits are offered in well or tube-based extraction formats, and are compatible with a variety of qPCR instruments, offering flexibility and cost savings without compromising sensitivity.
Learn more: Cygnus Technologies’ AccuRes Kits
Cygnus Technologies, part of Maravai LifeSciences, provides off-the-shelf analytical
solutions and custom services for host cell protein (HCP) and other process-related
impurity detection, as well as BSL-1 compatible viral clearance solutions. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release.
Visit online: Cygnus Technologies